This is a summary of the European public assessment report (EPAR) for Nexium Control. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not ... European Medicines Agency, 3 weeks ago
IT Business Information and Reporting Capability Lead, Europe - PharmaDiversity, 2 weeks ago
Reporting and Big data Capability Lead - PharmaDiversity, 1 month ago
3 images for "nexium"
AstraZeneca Plc (AZN), raised its forecast after reporting quarterly profit that beat analyst estimates, helped by a $200 million payment from one-time suitor Pfizer Inc. for rights to an over-the-counter version of the Nexium heartburn treatment. ...BusinessWeek, 1 month ago
Thales achieves successful testing of NEXIUM Wireless broadband 4G/LTE standard professional mobile radio by EDF users
Thales, a provider of services and solutions for aerospace, defence, transportation and security markets, announced on Wednesday that its NEXIUM Wireless broadband 4G/LTE standard professional mobile radio (PMR) solution has been successfully ...Individual.com, 1 month ago Thales Tests LTE PMR Solution With French Utility (7/2/14) Radio Resource Magazine, 1 month ago
Given the Sun-Ranbaxy merger, Nangra sees an upside potential of 8-10 percent in Ranbaxy.Money Control, 2 months ago Ranbaxy's FDA problems stymie launch of generic Nexium and the relief it would bring to consumers FiercePharmaManufacturing, 2 months ago Hold Ranbaxy Labs; target of Rs 615: KRChoksey Moneycontrol.com, 2 weeks ago Insurers balk at pricey generic version of ancient GSK heart drug FiercePharma, 1 month ago
After a long stretch of regulatory hassles, Vikas Dandekar of PharmAsiaNews.Com believes the worst is behind for the pharma major with this USFDA boost, a USD 3.4 billion opportunity.Money Control, 2 months ago Ranbaxy stock up 50% post deal with Sun Pharma Economic Times, 1 month ago U.S FDA Ban Ranbaxy: Stocks Dip! Silicon India, 1 month ago Ranbaxy, Sun Pharma up 6-8% on US FDA nod; analysts bullish Moneycontrol.com, 2 months ago
Rascal Flatts Joins the Thousands of People Who Choose Nexium® 24HR Every Day for Their Frequent Heartburn
Join Rascal Flatts Today and Choose Nexium 24HR - Satisfaction Guaranteed NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) announced today that the members of Rascal Flatts, the most-awarded country music band of the past decade, are among the ...Nasdaq, 3 weeks ago INTERVIEW: Rascal Flatts on finding their new EDM-tinged sound She Knows, 3 weeks ago AstraZeneca PLC Touts 2nd Quarter Results After Fending Off Pfizer Inc., CEO And Investors Rejoice BioSpace, 4 weeks ago Pfizer Releases 2Q 2014 Results Individual.com, 4 weeks ago
Monrovia — The Chief Executive Officer (CEO) of the Nexium Petroleum Limited in Liberia, has urged graduates of the Child Development Academy (CDA) high school to have confidence in their decisions and capabilities, while reminding them to nurture ...AllAfrica.com, 2 months ago
|Pharma In Focus, 1 week ago|
AstraZeneca has sued India-based generics firm Zydus Cadila to block its bid for a version of the brand manufacturer's acid-reflux drug Nexium. The lawsuit, filed July 31 in the U.S. District Court for the District of New Jersey, claims ...FDA News, 3 weeks ago AstraZeneca Has 30% Upside As A Takeover Candidate Seeking Alpha, 3 weeks ago AstraZeneca results to get lift from bid foe Pfizer 4 Traders, 1 month ago
AstraZeneca said Thursday that sales in the second quarter rose 4 percent year-over-year to $6.5 billion, topping analyst estimates of $6.3 billion, lifted by a $200-million payment from Pfizer for rights to an over-the-counter version of Nexium.FirstWord Pharma, 1 month ago AstraZeneca Ups '14 Outlook FOXBusiness.com, 1 month ago AstraZeneca beats expectations and raises forecasts after shooing off Pfizer MedCity News, 1 month ago AstraZeneca Raises 2014 Guidance Bidness Etc, 1 month ago
on your WebpageAdd Widget >Get your members hooked!